These experiments indicate that imlifidase eliminates both neutralizing anti‐FVIII antibodies and functional activity of emicizumab in hemophilia A. This might create the therapeutic window for efficient FVIII supplementation, while the short T1/2 of imlifidase allows for retreatment with emicizumab very shortly. The gene discussed is F8; the disease is hemophilia A.